Singapore HSA Brief

Headline

HSA initiates retail-level recall of seven BD ChloraPrep 1 mL Applicator batches over sterility breach risk

Executive Summary

Singapore's Health Sciences Authority issued a retail-level recall on July 17, 2026 covering seven batches of BD ChloraPrep 1 mL Applicator (Clear) due to potential packaging sterility breaches. The action requires removal of affected batches from retail and clinical supply chains.

Bottom Line

HSA's retail-level recall removes seven batches of BD ChloraPrep 1 mL Applicator (Clear) from lawful supply in Singapore on sterility-breach grounds. Healthcare facilities and distributors holding affected batch numbers are outside compliant supply-chain status until quarantine and return procedures are completed. The packaging-sterility basis places this action at the serious patient-safety tier for any facility using the product in pre-procedural antisepsis.

Key Regulatory Signals

• Sterility Breach Drives Retail-Level Action: HSA classified this as a retail-level recall, meaning affected product must be withdrawn from all points of sale and distribution. The sterility concern originates in the packaging, not the antiseptic formulation itself.
• Seven Batches in Scope: The recall covers seven discrete batches of BD ChloraPrep 1 mL Applicator (Clear). Healthcare facilities, distributors, and retail pharmacies holding any of the identified batch numbers are within the recall population.
• Clinical-Use Exposure: ChloraPrep applicators are used for skin antisepsis before invasive procedures. A packaging sterility failure in this product class carries direct patient-safety implications for any facility that has not yet quarantined affected stock.
• Distributor and Facility Response Required: Retail-level classification under HSA's recall framework requires the Singapore distributor and downstream holders to cease supply, quarantine stock, and initiate return or destruction procedures in accordance with HSA's product recall guidelines.

Regulatory Delta

- HSA has conducted prior medical-device and health-product recalls under its standard retail-level framework. This action follows that established procedure without structural departure.

- The sterility-breach basis distinguishes this from cosmetic or labeling recalls, placing it at the serious-harm tier given the product's use in invasive procedures.

- No equivalent recall announcement from the U.S. FDA or other regional authority appears in the source release. Cross-border batch exposure cannot be confirmed from available primary-source material.

Materiality Classification

MEDIUM — A retail-level sterility recall covering seven batches of a clinical-use antiseptic applicator; the compliance and quarantine obligation falls on all Singapore distributors and healthcare facilities holding affected stock, extending beyond the named manufacturer.

Intelligence Outlook

Monitor HSA for publication of the specific affected batch numbers, distributor return instructions, and any escalation to a higher recall classification if additional batches are implicated.